Gallbladder cancer (GBC) is the most common malignant tumor of the biliary tract system. Epithelial-mesenchymal transition (EMT) plays a vital role in the process of tumor metastasis. Mesenchymal-like cells can serve as a source of cancer stem cells, which can confer the EMT phenotype. Placental growth factor (PLGF) belongs to the vascular endothelial growth factor family and plays a vital role in cancer. However, the underlying molecular mechanisms about the influence of PLGF on EMT in GBC remain unknown. Here we show that PLGF expression levels were higher in GBC tissues than in normal adjacent tissues and were associated with poor progno- Huaifeng Li and Yunpeng Jin contributed equally to this work.
| INTRODUCTION
Gallbladder cancer is the most common malignant tumor of the biliary tract system with an incidence of approximately 2.5 cases per 1 9 10 5 people. [1] [2] [3] Despite the lower incidence of GBC compared with other gastrointestinal cancers, the survival rate for GBC is poor, due to the high degree of malignancy and high mortality. [2] [3] [4] [5] [6] More attention should be given to the exact mechanisms contributing to GBC initiation and development.
Metastasis is a multistage process that includes ECM remodeling, blood vessel recruitment, tumor cell entry and exit from the circulation, and survival at a distant organ. 7 Epithelial-mesenchymal transition plays a vital role in the tumor metastatic process. 8, 9 Previous studies have confirmed that EMT is dynamically controlled by various pro-invasion signals from the tumor microenvironment. 10 The tumor microenvironment comprises cells and factors, such as growth factors, inflammatory factors, and angiogenesis factors. 11 Chronic inflammation represents an important risk factor in the formation of GBCs. Chronic inflammation causes DNA damage and releases cytokines and growth factors. 12 Placental growth factor belongs to the vascular endothelial growth factor family. Placental growth factor is dispensable for development and health but plays a prominent role in pathology, including in cancer. 13 In addition to its angiogenic effects, PLGF contributes to metastasis and is considered a useful prognostic marker of cancer progression. Placental growth factor is overexpressed, and its expression is correlated with tumor stage, disease progression, recurrence, metastasis, and patient survival. [13] [14] [15] [16] [17] [18] However, the biological and pathological roles of PLGF in GBC are relatively less understood.
Here, we found that PLGF overexpression promoted GBC cell stemness and metastasis. Furthermore, miR-19a upregulation in GBC was associated with the amplification of PLGF and additional downstream signaling pathways. Evidence for PLGF functionality in GBC was also extended to the clinicopathological features and prognosis of GBC patients and could be considered for the development of potential therapeutics against GBC.
| MATERIALS AND METHODS

| Tissue samples
Human GBC samples and the corresponding normal gallbladder tissues were obtained from the Department of General Surgery, Xinhua
Hospital (Shanghai, China) between 2008 and 2013. The tissue samples were sent for histological analysis and diagnostic confirmation.
This study was approved by the research ethics committee, and written informed consent was obtained from all participants. The clinical features of the patients are listed in Table 1 .
| Cell culture and reagents
GBC-SD and 293T cells were purchased from the cell bank of the type culture collection of the Chinese Academy of Sciences (Shanghai, China). NOZ and H69 cells were obtained from the Health Science Research Bank (Osaka, Japan). All of the cells were maintained in high-glucose DMEM (Gibco, USA) supplemented with 10% FBS (Gibco) and penicillin G/streptomycin (100 U/mL, 100 g/mL;
Gibco). The cells were maintained as monolayer cultures at 37°C in humidified air with 5% CO 2 and 95% air. Recombinant PLGF was purchased from R&D Systems (USA).
| Protein isolation and immunoblot analysis
RIPA buffer (Sigma-Aldrich, USA) with Protease Inhibitor Cocktail (Roche Applied Science, USA) was used to isolate proteins from cells or tissues. Antibodies against PLGF were purchased from Proteintech (10642-1-AP; USA). Antibodies against Sox2 and Oct4 were purchased from Abcam (ab97959 and ab19857, respectively; Abcam, USA). Antibodies against Snail, Slug, N-cadherin, E-cadherin, C-MYC, PTEN, and b-actin were purchased from Cell Signaling Technology (#3879, #9585, #13116, #14472, #13987, #9188, and #3700, respectively; USA). Horseradish peroxidase-linked anti-rabbit IgG (#7074; CST, USA) and HRP-linked anti-mouse IgG (#7076; CST, USA) were used as secondary antibodies to detect the proteins.
| RNA extraction and qRT-PCR
Total RNA was extracted from the tissue samples or cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocols. Quantitative real-time PCR was carried out using SYBR Green (Takara, Japan) according to the manufacturer's instructions. The qRT-PCR results were analyzed and examined as the relative miRNA or mRNA levels based on CT values, which were converted to fold changes. The primer sequences used are listed in Table S1 . 
| Sphere-formation assays
Sphere-formation assays were carried out according to the methods described by Wang et al 19 The numbers of spheres >50 lm in diameter were counted under a microscope (Leica, Germany).
| Cell migration and invasion assays
The cell scratch, migration, and invasion assays were undertaken as previously described. 
| Cell transfection
Hsa-miRNA mimics, hsa-miRNA inhibitors, and their cognate control Table S2 . 
| Luciferase reporter assay
Luciferase reporter assays were carried out as described previously. 20 The miR-19a binding sites were determined according the investigation of Jia et al 21 2.11 | In vivo animal study 
| Immunohistochemistry
Immunohistochemistry was carried out using anti-N-cadherin ( 
| Statistical analysis
All experiments were repeated three times unless otherwise noted.
The data are presented as the mean AE SD. Two-tailed Student's t- 3 | RESULTS
| Placental growth factor is upregulated in GBC tissues and is associated with metastasis and poor patient survival
First, we examined PLGF protein levels in 10 pairs of human GBC tissues and NATs. We found that PLGF protein levels were significantly higher in GBC tissues than in NATs ( Figure 1A ). We further examined the mRNA levels of PLGF in another 39 pairs of human GBC tissues and NATs. Consistent with the protein levels, the average PLGF mRNA level was significantly higher in GBC tissues than in NATs ( Figure 1B ). To determine whether PLGF levels correlated with the OS of GBC patients, these 39 patients were followed up for 5 years. Thirty-nine GBC patients were divided into two groups (PLGF-low, n = 19; PLGF-high, n = 20) by setting the cut-off value to the median PLGF expression level. Kaplan-Meier curves showed that GBC patients with higher PLGF expression had a significantly shorter OS (P = .0375, Figure 1C ). The mean survival time in the PLGF-high group was 13.78 months, whereas the mean survival time in the PLGF-low group was 27.32 months. A clinicopathological association study of the 39 GBCs showed that PLGF was significantly associated with tumor invasion (P = .025) and lymph node metastasis (P = .026; Table 1 ).
| Placental growth factor promotes GBC cell migration, invasion, and stemness in vitro
The findings above revealed the prognostic value of PLGF in GBC, so we then addressed the role of PLGF in GBC cells. First, we examined the mRNA and protein expression levels in a series of GBC cell lines and normal cell lines. The H69 cell line was used as a representative of non-tumorigenic biliary epithelial cells. Compared with H69, the expression level of PLGF in GBC cell lines was obviously increased. Among them, the PLGF expression level in NOZ was much higher than that in GBC-SD (Figure 2A,B) . Therefore, we selected NOZ for knockdown and GBC-SD for overexpression.
We further investigated the functional role of PLGF in GBC progression. Epithelial-mesenchymal transition plays a key role in tumor progression and metastasis, in which epithelial cells obtain the migratory and invasive abilities of mesenchymal cells. 8, 9 To investigate the effects of PLGF on GBC cells, we decreased PLGF expression by transfecting siRNA against PLGF and exogenously increased PLGF expression by treating GBC cells with recombinant PLGF (100 ng/ mL). 22 To gain insight into the role of PLGF in cell metastasis, Transwell migration and Matrigel invasion assays were carried out in vitro.
After siRNA transfection, PLGF expression was significantly lower in the si-PLGF-1 (si-1) and si-PLGF-2 (si-2) groups than in the si-NC group ( Figure 2C ). Following transfection with si-1 and si-2, NOZ cells showed decreased cell migration and invasion ability ( Figure 2D , left, E). After treatment with PLGF for 24 hours, GBC-SD migration and invasion were increased nearly 1.5-fold compared with those of cells without PLGF. Moreover, after 48 hours, the increase was nearly 2-fold ( Figure 2D , right, F).
We also used the CCK8 assay to ascertain whether PLGF promotes the migration and invasion ability of GBC cells by promoting cell proliferation. There was no difference between the NC group and si-PLGF group or PLGF-treated group in terms of cell proliferation ( Figure S1a,b) , which means that PLGF promotes tumor migration and invasion ability without the effect of cell proliferation.
To determine whether PLGF induces EMT, the expression of EMT markers was evaluated. As shown in Figure 2 Numerous studies have reported that CSCs are responsible for heterogeneity, metastasis, drug resistance, and disease recurrence. 23 ,24 Therefore, we also undertook sphere-formation assays to | 1535 investigate the effect of PLGF on GBC CSC properties. Notably, spheres generated from exogenous PLGF-treated GBC-SD cells were larger in size than those generated from control cells ( Figure 2I,J) .
The CSC marker c-MYC, shown to be a key factor required for stem cell reprogramming, 25, 26 was highly induced at the protein level in the PLGF-treated group, unlike in the control group. Furthermore, another two CSC markers (Oct4 and Sox2) were significantly highly expressed in PLGF-treated cells ( Figure 2K, right) . By contrast, after PLGF knockdown, the three markers were significantly downregulated compared to those in the si-NC group ( Figure 2K, left) . Collectively, these data indicated that PLGF might play an important role in GBC EMT and tumorsphere formation. 
MicroRNA-19a, by binding to the 3ʹ-UTR, regulates multiple tar-
get genes, including PTEN, which is associated with EMT and CSC formation. [30] [31] [32] Thus, we detected PTEN protein levels after treatment with the miR-19a mimic or inhibitor ( Figure 4H ). Furthermore, we constructed a dual-luciferase reporter plasmid containing a fragment of the PTEN 3ʹ-UTR ( Figure 4I ). The dual-luciferase reporter assay showed that miR-19a mimics significantly reduced the luciferase activity in the PTEN wild-type group but had no effect on the PTEN mutated group (Fig. 4J) . The results revealed that PTEN is the target of miR-19a in GBC cells.
| MicroRNA-19a promotes metastasis in vivo
To determine whether miR-19a could regulate the metastasis of GBC (Fig. 5A,B) . The migration and invasion assay results showed that the PLGFmediated oncogenic phenotypes on GBC-SD cells were weakened after transfection with Lv-antagomir-19a, indicating that PLGF could promote GBC-SD cell metastasis by increasing miR-19a (Fig. 6A,B) .
The sphere-formation assay results confirmed that PLGF could enhance GBC-SD cell stemness through miR-19a ( Figure 6C,D) . Furthermore, we investigated the protein level of PTEN, EMT markers, and CSC markers after treatment with PLGF and infected them with antagomir-19a lentivirus. As shown in Figure 6 (E), when the antagomir-19a lentivirus was used to neutralize the tumor-promoting effects of PLGF, the levels of PTEN, a miR-19a target gene, were also recovered. A similar effect was observed for the EMT and CSC markers ( Figure 6E) . However, the level of c-MYC was not recovered. Taken together, these results revealed a PLGF/c-MYC/miR19a/PTEN regulatory axis in GBC cells ( Figure 6F ).
| DISCUSSION
The tumor microenvironment promotes cancer progression and is used to predict the phenotypic characteristics of cancer. 11 Most GBC patients have chronic cholecystitis, and gallstones are the main risk factor for the development of GBC. 2 Placental growth factor, a member of the vascular endothelial growth factor family, was initially identified as an angiogenic factor. 14 Interestingly, PLGF plays a vital role in tumor angiogenesis and metastasis and may be an unfavorable progression indicator for cancer patients. [13] [14] [15] [16] [17] 33, 34 However, the precise molecular mechanisms by which PLGF influences various physiological processes of GBC remain unknown. In the present study, we found that PLGF is highly expressed in GBC tissues.
Tumor cell metastasis is a complex and multistage process that includes adhesion, migration, invasion, angiogenesis, and eventual unremitting proliferation in distant target organs. 35 During tumor metastasis, EMT has been indicated to lead to the dissemination of single tumor cells from primary epithelial tumors. The EMT could be affected by various pro-invasion signals from the tumor microenvironment. Growing evidence has indicated that EMT is stimulated by certain cytokines and growth factors, such as transforming growth factor-b1. As an angiogenic factor, PLGF can induce EMT in human breast cancer cells. 36 Mounting evidence has revealed that CSCs are associated with EMT, and EMT cells can serve as the source of CSCs, which also confer the EMT phenotype. 37 The overlapping of these two properties suggests that they might be controlled by similar pathways. Therefore, it is important to identify whether target of c-MYC, the miR-17~92 cluster was found to be highly F I G U R E 4 MicroRNA-19a (miR-19a) promotes gallbladder cancer (GBC) cell metastasis and stemness in vitro. A-C, Cell migration and invasion assays were carried out in NOZ and GBC-SD cells that were transfected with equal doses of mimic negative control (NC), miR-19a mimic, inhibitor NC, or miR-19a inhibitor. A, Representative images are shown. Scale = 100 lm. B, C, Quantitative analysis of the number of migrated and invaded cells. *P < .05; **P < .01. D, E, Wound-healing assays were used to reveal the migration of treated NOZ cells. D, Representative images are shown. Scale = 100 lm. E, Quantitative analysis of wound closure. **P < .01; ***P < .001. 
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